Lymphoma Clinical Trials

Showing 381-400 of 3,379 trials

A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma

NCT05149391

This is a single-center, open-label study to evaluate the safety and efficacy of C-CAR039 in relapsed and/or refractory B cell Non-Hodgkin's Lymphoma patients.

B Cell Non-Hodgkin's Lymphoma

Peking University3 participantsStarted Jul 2021

Beijing, China

Active Not RecruitingPhase 2

Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

NCT05583149

This research is being done to assess the effectiveness and safety of acalabrutinib combined with lisocabtagene maraleucel (liso-cel) for people with relapsed/refractory aggressive B-cell lymphoma. This research study involves the study drug acalabrutinib in combination with lisocabtagene maraleuce

Refractory Aggressive B-cell LymphomasRefractory B-Cell Non-Hodgkin LymphomaAggressive B-cell NHL+10 more

Patrick C. Johnson, MD28 participantsStarted Mar 2023

Boston, Massachusetts, United States • Boston, Massachusetts, United States

Active Not RecruitingPhase 1

Venetoclax Plus Inotuzumab for B-ALL

NCT05016947

This research study is evaluating the safety and efficacy of administering venetoclax and inotuzumab ozogamicin in combination in patients with acute lymphoblastic leukemia (ALL) The names of the study drugs involved in this study are: * Venetoclax * Inotuzumab ozogamicin * Dexamethasone

B-cell Acute Lymphoblastic LeukemiaB-Cell LymphomaALL

Dana-Farber Cancer Institute23 participantsStarted Sep 2021

Boston, Massachusetts, United States • Boston, Massachusetts, United States

A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma

Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

Venetoclax Plus Inotuzumab for B-ALL

Related Searches

Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)

Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment

Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma

Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients

Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms

A Study of Bosmolisib (BR101801) in Participants With R/R PTCL.

Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL.

Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCL

Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma

PET and EBV DNA-directed Therapy for Localized Nasal Extranodal NK/T Cell Lymphoma

IMM0306 in Combination With Lenalidomide vs Placebo in Combination With Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma

Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation

Long-term Outcomes Associated With Juvenile-onset Mycosis Fungoides and Lymphomatoid Papulosis

Clinical Study of Universal CD19 CAR-γδT Cell Injection in the Treatment of Adult Relapsed/Refractory B-cell Lymphoma

Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma

MT2017-45: CAR-T Cell Therapy for Heme Malignancies

Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders